共 405 条
[1]
Kordower JH(2013)Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease Brain 136 2419-2431
[2]
Olanow CW(2015)MDS research criteria for prodromal Parkinson’s disease Mov Disord 30 1600-1611
[3]
Dodiya HB(2014)Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson’s disease Mov Disord 29 454-462
[4]
Chu Y(2008)Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy Neurology 71 1796-1803
[5]
Beach TG(2011)Preclinical biomarkers of Parkinson disease Arch Neurol 68 22-30
[6]
Adler CH(2004)Biomarkers of neurodegenerative disorders: how good are they? Cell Res 14 347-358
[7]
Berg D(2015)Can the disease course in Parkinson’s disease be slowed? BMC Med 13 295-292
[8]
Postuma RB(2010)Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy EPMA J 1 273-108
[9]
Adler CH(2013)The PRIPS study: screening battery for subjects at risk for Parkinson’s disease Eur J Neurol 20 102-772
[10]
Bloem BR(2014)Prodromal features for Parkinson’s disease - baseline data from the TREND study Eur J Neurol 21 766-1746